Good analysis. Further to it adding to an already approved treatment - there is two points.
1) OPT302 may still actually have potential single agent efficacy (that could potentially rival Lucentis) ... this would be pretty big news but has a lower probability.
2) It is really not just "adding" to the treatment, it is finishing off the puzzle of VEGF pathway blockade. For those among us that have studied these types of pathways, this also has some big implications to other related treatments.
As above, having clear easy to measure, quick endpoints is a huge plus for ANY trial design across lots of biotechs.
Exciting stuff!
Always DYOR, my insights only.
Cheers,
Sol
- Forums
- ASX - By Stock
- Ann: Opthea reports positive data from Phase 1 wet AMD Trial-OPT.AX
Good analysis. Further to it adding to an already approved...
-
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OPT (ASX) to my watchlist
|
|||||
Last
38.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $467.8M |
Open | High | Low | Value | Volume |
38.0¢ | 39.0¢ | 37.5¢ | $176.6K | 463.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 121324 | 38.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
39.0¢ | 90033 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 95009 | 0.380 |
6 | 189166 | 0.375 |
13 | 300856 | 0.370 |
4 | 11693 | 0.365 |
7 | 278244 | 0.360 |
Price($) | Vol. | No. |
---|---|---|
0.390 | 75043 | 2 |
0.395 | 13157 | 1 |
0.400 | 140733 | 2 |
0.405 | 30000 | 1 |
0.410 | 98513 | 3 |
Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
Featured News
OPT (ASX) Chart |